Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06162676 · ClinicalTrials.gov registry record · NA
Game-Based Intervention to Promote HPV Vaccination
A NA study of HPV Infection and Vaccine-Preventable Diseases, sponsored by Michigan State University.
- Active
- Registry status
- NA
- Development phase
- 131
- Enrollment target
- 1
- Study location
NCT06162676: Active NA study of HPV Infection and Vaccine-Preventable Diseases, sponsored by Michigan State University.
NCT06162676 is a NA study of HPV Infection and Vaccine-Preventable Diseases that is active but no longer recruiting, run by Michigan State University. The registered enrollment target is 131 participants, below the 226-participant average among 13 other HPV Infection trials with a reported enrollment target (42% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06162676, a NA study of HPV Infection and Vaccine-Preventable Diseases, is active but no longer recruiting, sponsored by Michigan State University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 131 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine the feasibility and acceptability of an innovative game-based intervention designed for families of youth aged 11-14 to promote HPV vaccination; will explore changes in key outcomes and related measures; and will identify factors contributing to or impeding effective implementation in health clinic settings. The intervention and its approach have the potential to reduce health disparities in HPV-associated cancers in youth via low-cost technology and timely intervention.
Primary Outcome
Assessed by the % of eligible individuals agreeing to participate
Conditions Studied
Interventions
- BEHAVIORAL HPV game
Study Locations (1)
Michigan
- Michigan State University - East Lansing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2026-02-28 |
| Phase | NA |
What the registry record for NCT06162676 still lists
NCT06162676 is an interventional study that assigns participants to a tested intervention. The registered 131 participants enrollment target is mid-sized for trials with a published cap, below the 226-participant average among 13 other HPV Infection trials with a reported enrollment target (42% lower).
The record links to 2 conditions, with HPV Infection appearing as the primary indexed condition, and to 1 intervention - of which HPV game is the first listed.
NCT06162676 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT06162676 about?
NCT06162676 is a clinical study titled "Game-Based Intervention to Promote HPV Vaccination". This study will examine the feasibility and acceptability of an innovative game-based intervention designed for families of youth aged 11-14 to promote HPV vaccination; will explore changes in key outcomes and related measures; and will identify factors contributing to or impeding effective implemen...
What is the current status of trial NCT06162676?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 131 participants. The study started on 2024-04-01. Estimated completion is 2026-02-28.
What conditions does trial NCT06162676 study?
This clinical trial studies the following conditions: HPV Infection, Vaccine-Preventable Diseases.
What interventions are being tested in trial NCT06162676?
The interventions under investigation include: HPV game (BEHAVIORAL).
Who is sponsoring clinical trial NCT06162676?
This trial is sponsored by Michigan State University, which has 120 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06162676 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HPV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06162676's enrollment target sits among peer trials
131 6th of 13 higher than 8 of 13 other HPV Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HPV Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
PCOM2 - The Physician Communication Intervention, Version 2.0
RECRUITING · NA
-
Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer
RECRUITING · NA
-
SELF-CERV Pivotal Study: SELF-Collection for CERVical Cancer Screening
ACTIVE NOT RECRUITING · NA
-
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
RECRUITING · Phase 4
-
Feasibility of HPV Testing With Mail-delivered Sample Collection Kits
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03051464 · 131 participants · Phase 2
No Surgery Trial / Two Dose-escalation Strategies
- NCT04301843 · 131 participants · Phase 2
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
- NCT04748549 · 131 participants · NA
Intraoperative VR for Older Patients Undergoing TKA
- NCT05951179 · 131 participants · Phase 2
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI